A Multi-institutional Study of Prevalence and Clinicopathologic Features of Non-invasive Follicular Thyroid Neoplasm With Papillary-like Nuclear Features (NIFTP) in Korea by �꽌�옄�쁺 et al.
378
pISSN 2383-7837
eISSN 2383-7845
© 2019 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/ 
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The follicular variant of papillary thyroid carcinoma (FVPTC) 
is the second most common type of papillary thyroid carcinoma 
(PTC) and accounts for 5%–41% of all PTC subtypes.1-4 FVPTC 
comprises two major subtypes: infiltrative FVPTC and encap-
sulated FVPTC (EFVPTC).5 The incidence of EFVPTC has grad-
ually increased over the past two decades and constitutes more 
than 10% of all thyroid malignances diagnosed in North America 
and Europe.6 EFVPTC can be further classified into two sub-
types: invasive EFVPTC and non-invasive EFVPTC based on 
the status of capsular or vascular tumor invasion.7 The majority 
of non-invasive EFVPTCs behave as indolent non-malignant 
tumors and have been renamed as non-invasive follicular thyroid 
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Background: In the present multi-institutional study, the prevalence and clinicopathologic characteristics of non-invasive follicular thy-
roid neoplasm with papillary-like nuclear features (NIFTP) were evaluated among Korean patients who underwent thyroidectomy for 
papillary thyroid carcinoma (PTC). Methods: Data from 18,819 patients with PTC from eight university hospitals between January 2012 
and February 2018 were retrospectively evaluated. Pathology reports of all PTCs and slides of potential NIFTP cases were reviewed. 
The strict criterion of no papillae was applied for the diagnosis of NIFTP. Due to assumptions regarding misclassification of NIFTP as 
non-PTC tumors, the lower boundary of NIFTP prevalence among PTCs was estimated. Mutational analysis for BRAF and three RAS 
isoforms was performed in 27 randomly selected NIFTP cases. Results: The prevalence of NIFTP was 1.3% (238/18,819) of all PTCs 
when the same histologic criteria were applied for NIFTP regardless of the tumor size but decreased to 0.8% (152/18,819) when tumors 
≥ 1 cm in size were included. The mean follow-up was 37.7 months and no patient with NIFTP had evidence of lymph node metasta-
sis, distant metastasis, or disease recurrence during the follow-up period. A difference in prevalence of NIFTP before and after NIFTP 
introduction was not observed. BRAFV600E mutation was not found in NIFTP. The mutation rate for the three RAS genes was 55.6% 
(15/27). Conclusions: The low prevalence and indolent clinical outcome of NIFTP in Korea was confirmed using the largest number of 
cases to date. The introduction of NIFTP may have a small overall impact in Korean practice.
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neoplasm with papillary-like nuclear features (NIFTP).8 This 
introduction of NIFTP concept has significantly affected clinical 
practice by reducing the therapeutic intensity for patients with 
EFVPTCs.
Differentiating NIFTP from invasive EFVPTC solely based 
on cytomorphologic findings is impossible when using thyroid 
fine needle aspiration cytology. NIFTPs are mostly interpreted as 
indeterminate categories.9 The two most common genetic muta-
tions found in thyroid tumors are BRAF and RAS point muta-
tions.10 RAS mutations occur in 30%–40% of EFVPTCs.11-14 
The BRAFV600E mutation is absent in NIFTPs but can occur in 
up to 30% of invasive EFVPTCs.14,15
In Korea, a low rate of NIFTP has been reported in several 
studies.16-18 However, the studies were limited by small sample 
size and single institution, and the results might not represent 
the general population. Therefore, in the present study, the prev-
alence of NIFTP among Korean patients was evaluated by re-
viewing multicenter-based data using the largest cohort size to 
date in Korea. 
MATERIALS AND METHODS
Study cohort
Data from 18,819 patients with PTC from eight university 
hospitals were retrospectively analyzed. The tumors were diag-
nosed from surgically resected specimens between January 
2012 and February 2018. The slides of all cases initially diag-
nosed as EFVPTC on pathology reports were reviewed and re-
classified into NIFTP, invasive EFVPTC, and other PTC subtypes. 
The NIFTP was diagnosed according to the criteria of World 
Health Organization (WHO) Classification of Tumours of Endocrine19 
and recently revised diagnostic criteria:20 (1) encapsulation or 
clear demarcation of the tumors (thick, thin, or partial capsule, 
or well circumscribed with a clear demarcation from adjacent 
thyroid tissues), (2) follicular growth pattern with no papillae 
(including microfollicular, normofollicular, or macrofollicular 
architecture with abundant colloid) with no psammoma bodies 
and < 30% solid/trabecular/insular growth pattern, (3) nuclear 
score 2–3, (4) no capsular or vascular invasion (requires ade-
quate microscopic examination of the tumor capsule interface), 
(5) no tumor necrosis, (6) no high mitotic activity (high mitotic 
activity defined as at least 3 mitoses per 10 high-power fields 
(400 ×) (Fig. 1). A nuclear score of 2–3 is diagnostic of NIFTP. 
However, if florid nuclear features (nuclear score 3) of PTC are 
present, a meticulous histopathologic examination of the entire 
tumor is required for the detection of any true papillae, psam-
moma bodies, aggressive histology, or invasion into tumor cap-
sule or vessels. 
Molecular analysis of NRAS and HRAS genes
Molecular analysis of 27 NIFTP cases obtained from a single 
institution was performed. Genomic DNA was extracted from 
paraffin-embedded thyroid specimen blocks. The representative 
slides were selected and the tumor tissues were manually dis-
sected under a stereomicroscope and stored in a 1.5 mL tube. 
Genomic DNAs were extracted from 5–10-μm-thick tissue 
sections using the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Exon 3 
of NRAS and HRAS genes was amplified using polymerase chain 
reaction (PCR) with the following primers: (1) NRAS-exon 3–197 
bp, forward (5'-CCCCTTACCCTCCACACC-3') and reverse 
(5'-GAGGTTAATATCCGCAAATGACTT-3'); (2) HRAS-exon 
3–201 bp, forward (5'-GTCCTCCTGCAGGATTCCTA-3') and 
reverse (5'-CGGGGTTCACCTGTACT-3'). The PCR cycling 
conditions for NRAS and HRAS mutations were as follows: initial 
activation at 94°C for 15 minutes; 35 cycles at 94°C for 30 sec-
onds, 51°C–57°C for 30 seconds, 72°C for 30 seconds, final ex-
tension at 72°C for 10 minutes. The amplicons were analyzed 
using 2% agarose gel electrophoresis and purified using QIA-
quick PCR purification kit (Qiagen). The amplified PCR prod-
ucts were sequenced using Sanger sequencing. The amplicons 
were evaluated on 2% agarose gel electrophoresis and purified 
using the QIAquick PCR purification kit (Qiagen). The ampli-
fied PCR products were analyzed using the automated se-
quencing machine ABI 3730 (Applied Biosystems, Foster City, 
CA, USA), which performed Sanger sequencing using the same 
PCR primers.17
Molecular analysis of KRAS gene
For detection of the KRAS mutation, a PNAClamp KRAS 
mutation detection kit (Panagene, Daejeon, Korea) was used. 
The following reagents were used in all PCR reactions (total vol-
ume, 20 µL): 10 ng template DNA, primer, peptide nucleic acid 
(PNA) probe set, and SYBR Green PCR Master Mix. A CFX 
96 (Bio-Rad, Hercules, CA, USA) was used for the real-time 
PCR of PNA-mediated clamping. PCR cycling conditions con-
sisted of the following sequential steps: 5-minute hold at 94°C 
followed by 40 cycles at 94°C for 30 seconds, 70°C for 20 seconds, 
63°C for 30 seconds, and 72°C for 30 seconds. All seven muta-
tions in the KRAS gene were detected using one-step PNA-medi-
ated real-time PCR clamping. PNA probes and DNA primers were 
used for the corresponding clamping reaction. SYBR Green flu-
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orescent dye was applied for the detection of positive reaction 
signals. The amplification of the wild-type target was suppressed 
by the PNA probe sequence complementary to wild-type DNA. 
Due to this suppression, the amplification of mutant sequences 
was specifically preferred by competitive inhibition of DNA 
primers binding to wild-type DNA. The threshold cycle (Ct) value 
was used to evaluate PCR efficiency. The SYBR Green amplifi-
cation plots were generated to analyze Ct values for the control 
and mutation assays. Mutation status was determined by Ct 
value differences ≥ 2, which were obtained between the control 
and samples.
Molecular analysis of BRAF gene
Mutational analysis of BRAF was performed using two dif-
ferent methods. The PNAClamp BRAF mutation detection kit 
(Panagene) was used to detect the BRAFV600E mutation. Each 
reaction tube had a total volume of 20 µL and included a mixture 
of template DNA, primers, PNA probe, and SYBR Green PCR 
Master Mix. Real-time PCR of PNA-clamping PCR was per-
formed using a CFX96 real-time PCR system (Bio-Rad, Pleas-
anton, CA, USA). The PNA probe was complementary to wild-
type (V600). PCR was performed under the following conditions: 
5-minute hold at 94°C, 40 cycles of 30 seconds at 94°C, 20 
seconds at 70°C, 30 seconds at 63°C, and 30 seconds at 72°C. 
A
D
B
C
E
Fig. 1. (A) A case of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): low power view, NIFTP composed 
entirely of a follicular growth pattern with complete encapsulation (scan view). (B) NIFTP shows a thick fibrous capsule without capsular and 
vascular invasion. (C) NIFTP with nuclear score 2. (D, E) Papillary thyroid carcinoma showing nuclear score 3. 
http://jpatholtm.org/https://doi.org/10.4132/jptm.2019.09.18
NIFTP Prevalence in Korea  •     381
The PNA probe and primers incorporated in the assay were sep-
arate oligonucleotides, and the PNA probe location was placed 
between forward and reverse primers within the template. Inter-
calation of SYBR Green fluorescent dye was used to detect posi-
tive signals.
Pyrosequencing for the BRAF mutation analysis was per-
formed as described in detail elsewhere.21 The primers used for 
PCR were the following: forward primer (5'-GAAGACCTCA-
CAGTAAAAATAG-3') and reverse primer (5'-biotin-ATAGCCT-
CAATTCTTACCATCC-3'). The pyrosequencing reaction was 
performed with a sequencing primer (5'-biotin-ATAGCCT-
CAATTCTTACCATCC-3') on a Pyromark Q24 instrument (Qia-
gen). The PyroMark Q24 software (Qiagen) was used for analysis of 
the pyrogram results.
Statistical analysis
Clinicopathological parameters of NIFTP before and after 
NIFTP introduction were analyzed using the chi-square test or 
Fisher’s exact test for categorical variables and the t-test for con-
tinuous variables. All statistical analyses were performed using 
SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA). A p-value of 
< 0.05 was considered statistically significant.
Ethics statement
The current study was approved by the Institutional Review 
Boards (IRBs) of eight institutions. Ethics approval for all proce-
dures performed in the current study was obtained from the IRB 
(approval No. 3-2018-0271). Formal written informed consent 
was waived by the IRB.
RESULTS
The prevalence of NIFTP in PTC cases
To evaluate the incidence of NIFTP in the Korean popula-
tion, data were retrospectively collected from the eight university 
hospitals in Korea. The incidence of NIFTP in each institution is 
shown in Table 1. After reviewing pathology reports of 18,819 
patients with PTC, 378 patients (2.0%) were initially diagnosed 
with non-invasive EFVPTC as potential NIFTP cases; 140 cases 
were excluded from NIFTP diagnosis after review of pathology 
slides acquired from 378 cases. The most common reason for 
exclusion was the presence of small, but true papillae that were 
rediagnosed as conventional PTC. Other reasons for exclusion 
were reclassification as infiltrative FVPTC or unavailability for 
slide review. Finally, 238 (1.3%) of all PTCs were eligible for the 
diagnosis of NIFTP after slide review. 
Among 238 cases of NIFTP, 174 cases (73.3%) had only 
NIFTP; in the remaining 64 cases (26.7%), NIFTP coexisted 
with other malignancies, such as conventional PTC, infiltrative 
FVPTC, tall cell variant PTC, oncocytic variant PTC, follicular 
carcinoma, or poorly differentiated carcinoma (Table 2). 
Because not all cases were available for slide review and NIF-
TP can be misclassified as non-PTC tumors, the lower boundary 
for the prevalence of NIFTP among PTCs was estimated. When 
the same histologic criteria was applied for the diagnosis of NIF-
TP regardless of the tumor size, the prevalence of NIFTP was 238 
(1.3%) among all PTCs. Among the reclassified 238 NIFTP 
cases, 86 had a tumor < 1.0 cm and 152 had a tumor ≥ 1.0 cm 
(Table 2). Therefore, the expected lower boundary for the preva-
lence of NIFTP was 0.8% (152/18,819) when tumors ≥ 1.0 cm 
were included for the diagnosis of NIFTP. 
Clinicopathologic characteristics of patients with NIFTP
Among 152 patients with NIFTP ≥ 1.0 cm in size, 125 (82.2%) 
patients had only NIFTP and the remaining 27 patients (17.8%) 
had NIFTP coexisting with thyroid cancer. The clinicopatho-
logic characteristics were evaluated in patients with only NIFTP. 
The demographics of 125 NIFTP patients are shown in Table 3. 
The mean age was 46.7 years (range, 23 to 73 years). The NIF-
Table 1. The prevalence of NIFTP in eight university hospitals
Institution Period PTC
Invasive 
EFVPTC
NIFTP 
A 2012–2017 1,427 44 (3.1) 26 (1.8)
B 2013–2016 1,342 35 (2.6) 35 (2.6)
C 2013–2017 3,927 192 (4.9) 100 (2.5)
D 2013–2017 6,200 134 (2.2) 24 (0.4)
E 2013–2017 3,083 37 (1.2) 23 (0.7)
F 2014–2017 734 9 (1.2) 5 (0.7)
G 2015–2017 1,077 2 (0.2) 20 (1.9)
H 2015–2018 1,029 14 (1.4) 5 (0.5)
Total 18,819 467 (2.5) 238 (1.3)
Values are presented as number (%).
NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear 
features; PTC, papillary thyroid carcinoma; EFVPTC, encapsulated follicular 
variant of PTC.
Table 2. Prevalence of NIFTP according to the tumor size among 
18,819 patients with initial diagnosis of papillary thyroid carcinoma
Total ≥ 1.0 cm < 1.0 cm 
All cases of NIFTP 238 (1.3) 152 (0.8) 86 (0.5)
NIFTP alone   174 (73.3)   125 (82.2)   49 (57.0)
NIFTP coexisting with malignancy     64 (26.7)     27 (17.8)   37 (43.0)
Values are presented as number (%).
NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear 
features.
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Table 3. Demographic and clinicopathologic features of 125 patients with NIFTP alone before and after NIFTP introduction
Overall Before NIFTP introductiona After NIFTP introduction p-value
Prevalence of NIFTP  125/18,819 (0.7) 66/9,656 (0.6) 59/9,163 (0.7) .739
Sex .004
Male 32 (25.6) 24 (36.4) 8 (13.6)
Female 93 (74.4) 42 (63.6) 51 (86.4) 
Age, mean ± SD (range, yr) 46.7 ± 12.5 (23–73) 47.9 ± 13.1 (23–73) 45.3 ± 11.9 (25–73) .238
Tumor size, median (range, mm) 26.2 (10–80) 24.5 (10–61) 28.0 (10–80) .195
No. of paraffin blocks, median (range) 5.3 (1–26) 5.2 (2–26) 5.5 (1–18) .398
Lymph node dissection .385
Performed 101 (80.8) 48 (72.7) 53 (89.8)
Not performed 24 (19.2) 18 (27.3) 6 (10.2)
Lymph node metastases > .99
Positive 0 0 0
Negativeb 125 (100) 66 (100) 59 (100)
Surgical procedure .021
Lobectomy or isthmectomy 81 (64.8) 37 (56.1) 44 (74.6)
Total thyroidectomy 44 (35.2) 29 (43.9) 15 (25.4)
Lymphatic invasion 1.000
Positive 0 0 0
Negative 125 (100) 66 (100) 59 (100)
Vascular invasion 1.000
Positive 0 0 0
Negative 125 (100) 66 (100) 59 (100)
Distant metastasis 1.000
Positive 0 0 0
Negative 125 (100) 66 (100) 59 (100)
Postoperative radioactive iodine therapy .365
Performed 29 (23.2) 17 (25.8) 12 (20.3)
Not performed 96 (76.8) 49 (74.2) 47 (79.7)
Follow-up, median ± SD (range, mo) 25.1 ± 19.1 (0–60) 36.2 ± 14.5 (0–60) 10.7 ± 6.6 (1–24)
Recurrence of disease 1.000
Positive 0 0 0
Negative 125 (100) 66 (100) 59 (100)
Values are presented as number (%) unless otherwise indicated.
NIFTP, non-invasive follicular thyroid neoplasm with papillary-like nuclear features; SD, standard deviation.
aBefore April, 2016; bIncludes pN0 and pNx stages.
TP patients included 93 females (74.4%) and 32 males (25.6%). 
The median primary tumor size was 26.2 mm (range, 10 to 
80 mm). Among 125 patients, 101 (80.8%) underwent cervical 
lymph node dissection and lymph node metastasis was not found. 
In addition, no patient had lymphatic/vascular invasion or dis-
tant metastases. Regarding surgical methods, a total of 44 pa-
tients (35.2%) underwent total thyroidectomy and 81 patients 
(64.8%) received lobectomy or isthmectomy. Furthermore, 29 
patients (23.2%) underwent radioactive iodine (RAI) remnant 
ablation therapy based on the initial tumor size. Disease recur-
rence was not observed in any NIFTP patient during a median 
follow-up period of 25.1 months.
Impact of NIFTP on pathologic examination and clinical 
practice
A difference in the prevalence of NIFTP before and after 
NIFTP introduction was not observed (Table 3). The number 
of paraffin blocks for diagnosis of NIFTP did not increase after 
the introduction of NIFTP (average 5.2 per tumor before April 
2016 and average 5.5 per tumor after April 2016).
The rate of lymph node dissection increased from 72.7% be-
fore April 2016 to 89.8% after April 2016. The rate of total 
thyroidectomy decreased from 43.9% before April 2016 to 
25.4% after April 2016. The number of patients undergoing 
postoperative RAI therapy was significantly reduced from 25.8% 
before April 2016 to 20.3% after April 2016 (Table 3). RAI 
treatment was performed due to coexisting thyroid cancers in 
most cases.
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BRAF and RAS mutations in NIFTPs
Twenty-seven patients diagnosed with NIFTP at the Gang-
nam Severance Hospital after April 2016 were randomly select-
ed for gene analysis; BRAFV600E mutation was not observed. As 
shown in Table 4, the overall frequency of three RAS gene mu-
tations was 55.6% (15/27). The mutation rates of NRAS, HRAS, 
and KRAS were 22.2%, 22.2%, and 11.1%, respectively.
DISCUSSION
The overall prevalence of NIFTP was 1.3% (range, 0.4% to 
2.6%) of all PTCs in the present study, which included the 
largest cohort size researched to date among the Korean popula-
tion (Table 1). According to the recent study by Nikiforov et 
al.,8 any masses < 1.0 cm were not included in the diagnosis of 
NIFTP. Moreover, in another recent NIFTP study, data on the 
sub-centimeter NIFTP were limited.22 Thus, the expected lower 
boundary for the prevalence of NIFTP was 0.8% when tumors 
≥ 1 cm in size were included in the diagnosis of NIFTP.
These results are consistent with the findings from a previous 
study in which the mean prevalence of NIFTP was 1.5% (range, 
0% to 4.7%) in nine institutions from six Asian countries, in-
cluding Korea.23 The prevalence of NIFTP is constantly lower in 
Asian studies than in Western population-based studies.22,24-27
NIFTPs frequently have RAS mutations but no BRAFV600E 
mutation.11-14 However, the BRAFV600E mutation was found in 
some NIFTP cases in several studies immediately performed af-
ter the initial publication of NIFTP.17,18,28,29 Table 5 summarizes 
the results of BRAF mutation in NIFTP reported in previous 
studies from six Korean institutions.17,18,28-31 When the strict crite-
rion of “0% papillae” was applied in the present study, no BRAF 
mutation was found in NIFTPs. In the present case series, a case 
of BRAFV600E-positive tumor originally diagnosed as non-inva-
sive EFVPTC was found. The pathology slides were re-examined 
after cutting deeper sections and a true papillary structure was 
found in a focal area. Therefore, the case was reclassified as en-
capsulated classic PTC with predominant follicular growth pat-
tern. This finding reconfirms the strict diagnostic criteria for NIF-
TP are helpful for excluding true PTC. Because the diagnostic 
criteria for NIFTP have been updated, NIFTP should no longer 
include any follicular patterned tumors with well-formed papillae 
or high-risk gene mutations such as BRAFV600E, TERT promoter, 
or TP53.20
The present study had several technical limitations. First, due 
to the retrospective multicenter-based nature of this study, inter-
observer variability in the diagnosis of NIFTP based on histology 
was not considered. Second, since only the cases diagnosed with 
PTC were included, the possibility that NIFTP was diagnosed 
as benign, such as nodular hyperplasia or follicular adenoma, may 
result in differences in actual prevalence. However, the prevalence 
of NIFTP did not change significantly even after the introduc-
tion of NIFTP. Third, although the overall study cohort size was 
relatively large, genetic analysis of BRAF and RAS mutations 
Table 5. Characteristics of NIFTP in Korean population reported in literature
Study Period
Diagnostic 
criteria
PTC NIFTP
No. (%)
BRAFV600E 
mutation
RAS 
mutation
Lymph node 
metastasis
Distant 
metastasis
Cho et al. (2017)17 2008–2014 < 1% papillae 6,269 105 10 (10.0)  - 3 (2.9) 1 (1.0)
0% papillae 6,269   95 0�������� 48/89 (53.9) 2 (2.1) 0��������
Kim et al. (2017)28 2009–2014 < 1% papillae 6,548   43 3 (7.0)  - 1 (2.3) 0��������
Lee et al. (2017)18 2010–2014 < 1% papillae 769   21   5 (23.8) 12 (57.1) 1 (4.7) 0��������
Kim et al. (2018)30 2011–2012 < 1% papillae 1,411     2 0��������  - 0�������� 0��������
Kim et al. (2018)31 2013–2016 0% papillae  -   32 0�������� 15 (46.9) 0�������� 0��������
Kim et al. (2018)29 2014–2016 < 1% papillae 2,853   73   9 (12.3) 36 (49.3)   9 (12.3) 0��������
NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PTC, papillary thyroid carcinoma.
Table 4. Molecular profiles of noninvasive follicular thyroid neo-
plasm with papillary-like nuclear features (n = 27)
Mutation No. (%)
BRAFV600E
Present 0�
Absent 27 (100)
All RAS mutation
Present 15 (55.6)
NRAS 6 (22.2)
c.181C > A (p.Gln61Lys) 3 (50.0)
c.182A > G (p.Gln61Arg) 3 (50.0)
HRAS 6 (22.2)
c.182A > G (p.Gln61Arg) 6 (100)
KRAS codon 61 mutationa 3 (11.1)
aKRAS mutation was analyzed by PNAClamp KRAS mutation detection kit. 
The assay cannot identify specific mutation types.
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were performed in only a limited number of NIFTP cases. Nev-
ertheless, the results were consistent with previous study results 
showing NIFTP has no BRAFV600E mutation and frequent RAS 
mutations.8,15,20
The results from this study has shown the low prevalence of 
NIFTP among PTCs in Korea using the largest number of cases 
to date. Adverse outcomes were not experienced by any patient 
with NIFTP during the follow-up period. The introduction of 
NIFTP may have a small overall impact in Korean practice.
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